about
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaAnaplastic lymphoma kinase: signalling in development and diseaseAnaplastic thyroid cancers harbor novel oncogenic mutations of the ALK geneIntegrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaThe role of the ALK receptor in cancer biologyTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureCell Proliferation in NeuroblastomaNeuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosisALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceChemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastomaClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesEmerging importance of ALK in neuroblastomaEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesTargeting EML4-ALK driven non-small cell lung cancer (NSCLC)Involvement of midkine in neuroblastoma tumourigenesisNeuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid raftsCrystal structure of the ALK (anaplastic lymphoma kinase) catalytic domainThe R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma KinaseThe neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Activating HER2 mutations in HER2 gene amplification negative breast cancerSafety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.The zebrafish as a model for studying neuroblastomaFocal DNA copy number changes in neuroblastoma target MYCN regulated genesFAM150A and FAM150B are activating ligands for anaplastic lymphoma kinaseInhibitors of the anaplastic lymphoma kinaseMolecular pathogenesis of peripheral neuroblastic tumorsRenal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrumDetectable clonal mosaicism in the human genomeALK and NSCLC: Targeted therapy with ALK inhibitorsInternalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatmentA p53 drug response signature identifies prognostic genes in high-risk neuroblastoma
P2860
Q28308636-50776458-27CF-43F7-8226-09FC7850943CQ54813265-496872F6-56BF-4261-A9AD-9F3D35CEA317Q54871616-3FDD751D-144F-412C-89C8-76EDEDC2129BQ54899802-606C39A3-8A78-4968-83EB-3746CDF1F6CEQ54901875-F5A3B165-D4BA-4745-AA17-BAD285420295Q54901876-A1D539CE-6339-4F6B-843C-176B0E65F579Q54901878-2D0333AD-621E-4D48-8130-3AC14099C872Q54907515-FBBB4EAF-3833-4079-BD35-6B68C0830207Q54907517-5C33E034-AE0F-46E9-981C-34F4846AAB25Q54907543-8E9B93DA-69F2-41F3-9E64-CAF36011FB6DQ54930502-110385D0-5287-43FC-B0CA-353BC859B261Q54952459-4A1DDC2C-8275-4930-A259-EB957FC4888DQ54952461-00E6A209-E073-4769-B1F9-8C1F7040ECA7Q54952462-25F76339-2413-4D25-84C5-EEEBF0C8B276Q54953553-AC4C6544-87FC-4429-B60F-24214253404AQ54953566-BEDDDE9E-F6AB-40A4-8CAB-190F5E33D871Q54953568-33DD1751-8001-4309-B314-58E28C02BF44Q54953569-1230A33E-3185-427B-9DC1-A6A21E6F8436Q54953577-74411A9F-A496-45D2-BBE4-6C77835F769DQ54953578-8EA7DBA5-C379-4A57-A207-0F7AB9B12029Q54953579-C77F4D28-5BD2-403B-9963-831FB5448EBBQ54953580-354C33AF-E85E-4EA8-BF00-F7BBC78CB531Q54972266-875DEA26-B030-4347-ABAE-92919D3535AFQ54992259-AD299463-00BE-4A04-87BE-6D6284C72984
P1343
Q24310296-46F7295C-1D15-4421-A055-EE04AB02FDC5Q24312329-39420666-DC54-4A3A-8983-6DD905D7F783Q24598210-BBB640F0-67C6-41F1-A62D-F1563CF87D11Q24630017-B8036981-AF11-4266-9DDF-3A2ABB3A388AQ26738384-25BAB93A-FB8E-494A-9C64-857A85A8338AQ26746934-45FEE6C9-0BE2-4A65-AE8B-861612E1BABDQ26771708-526AFE55-8E56-4301-8C00-3837ADB080A9Q26774960-6E6F68DE-BE91-45F0-9A4F-33664E37A0C0Q26775347-86F41EBB-80E2-42CC-AB1F-74D4CE19C49EQ26800007-73755543-B74B-4F3E-946D-F9CFE3903552Q26823978-65B9D356-5493-43F8-AFFA-8A9329D3D37EQ26858819-E8CDF71D-FAE4-4283-9193-4FF253BE328AQ26999187-DE9DD630-99CD-4A6F-B2A1-5EF046E0CE7EQ27002155-DEA33DEE-03BE-4299-B4A9-67A3B80AB5AAQ27026748-1265F0E3-E390-46FE-AD79-C00E2DD8596AQ27319837-F04F0C41-C38E-4035-9FD6-A853B19DF6F1Q27663479-E0662F94-EDCB-494A-973A-AC07241CF239Q27671787-0FF829F2-913F-4C8D-8FB1-0369F59F6AEBQ27851591-05A1E1A9-0CC8-4224-8EA6-49B296BCC0DAQ27851671-A3280114-C320-4DA5-B928-0C7F29920F06Q27851672-46700C15-9C92-4530-BEC6-DBF0C8750C87Q27851681-CB507EB9-F994-4C12-A31B-47B3C2101456Q27851684-1B6D445F-3025-43DC-A100-3891B62E2746Q27851702-5587513F-BACE-4A32-972C-BDD7D25B3DABQ27851710-3336D4B9-A78C-41ED-9EF6-C8DC85C1BD0AQ27851987-2B9CB852-9640-42EE-B103-A87EF2E8438FQ27852211-AF7B6FCF-21AF-4134-AB76-2ECFC891FED1Q27853241-8C63BCF9-3934-49DC-A8D3-8BA8FA1357FEQ27853323-F6DB316B-D0C5-4648-AC68-6095E12A96FEQ27853373-D875CAF6-A11C-4644-A5E5-5F30D62474A5Q28070309-C90D704A-BB8B-4868-8196-83A6E886E6AEQ28115604-D3005AF2-F32D-4930-A77E-D43275016F63Q28118071-E252E53E-9F27-4BE8-B127-1AD6C9ACCFAEQ28267124-786A91D0-3FF2-4563-B975-747FCD21F526Q28271405-1E0D2CEF-0836-470C-A38F-0296CCCBB002Q28298351-8CD998C7-5C95-4895-8184-DC7FE3E792BDQ28392522-C9179A6E-1379-4E2D-9936-4F46F161B433Q28393324-44A9854F-0414-4749-8743-DA7710FC00C0Q28482066-F378CC16-1A4D-4725-B677-EE10E175B18CQ28537647-AAB56D23-BC5B-47FB-A50D-10C89E9338D1
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Oncogenic mutations of ALK kinase in neuroblastoma.
@en
Oncogenic mutations of ALK kinase in neuroblastoma.
@nl
type
label
Oncogenic mutations of ALK kinase in neuroblastoma.
@en
Oncogenic mutations of ALK kinase in neuroblastoma.
@nl
prefLabel
Oncogenic mutations of ALK kinase in neuroblastoma.
@en
Oncogenic mutations of ALK kinase in neuroblastoma.
@nl
P2093
P4510
P356
P1433
P1476
Oncogenic mutations of ALK kinase in neuroblastoma.
@en
P2093
Akira Kikuchi
Akira Nakagawara
Hiroyuki Mano
Junko Takita
Manabu Soda
Masashi Sanada
Miki Ohira
Seishi Ogawa
Takashi Igarashi
P2888
P304
P356
10.1038/NATURE07399
P407
P577
2008-10-01T00:00:00Z
P6179
1006406211